Logo image of KAPA

KAIROS PHARMA LTD (KAPA) Stock Fundamental Analysis

NYSEARCA:KAPA - NYSE Arca - US48301N1046 - Common Stock - Currency: USD

0.8125  -0.04 (-5.14%)

Fundamental Rating

1

Taking everything into account, KAPA scores 1 out of 10 in our fundamental rating. KAPA was compared to 563 industry peers in the Biotechnology industry. KAPA may be in some trouble as it scores bad on both profitability and health. KAPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KAPA has reported negative net income.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -500K -1M -1.5M -2M

1.2 Ratios

Looking at the Return On Assets, with a value of -54.78%, KAPA is in line with its industry, outperforming 43.16% of the companies in the same industry.
KAPA has a Return On Equity of -82.26%. This is comparable to the rest of the industry: KAPA outperforms 51.51% of its industry peers.
Industry RankSector Rank
ROA -54.78%
ROE -82.26%
ROIC N/A
ROA(3y)-188.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 100 -100 -200

1.3 Margins

KAPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, KAPA has about the same amount of shares outstanding.
Compared to 1 year ago, KAPA has a worse debt to assets ratio.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 200K 400K 600K 800K 1M

2.2 Solvency

KAPA has an Altman-Z score of 2.37. This is not the best score and indicates that KAPA is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.37, KAPA is in the better half of the industry, outperforming 74.96% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that KAPA is not too dependend on debt financing.
KAPA has a Debt to Equity ratio of 0.04. This is in the lower half of the industry: KAPA underperforms 61.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 2.37
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 500K -500K -1M -1.5M -2M

2.3 Liquidity

A Current Ratio of 2.84 indicates that KAPA has no problem at all paying its short term obligations.
KAPA has a Current ratio of 2.84. This is in the lower half of the industry: KAPA underperforms 66.79% of its industry peers.
A Quick Ratio of 2.84 indicates that KAPA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.84, KAPA is not doing good in the industry: 65.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 2.84
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

KAPA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.49%.
EPS 1Y (TTM)-72.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KAPA will show a very negative growth in Earnings Per Share. The EPS will decrease by -42.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-44.58%
EPS Next 2Y-43.11%
EPS Next 3Y-45.56%
EPS Next 5Y-42.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KAPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KAPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

KAPA's earnings are expected to decrease with -45.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.11%
EPS Next 3Y-45.56%

More info and screens

0

5. Dividend

5.1 Amount

KAPA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAIROS PHARMA LTD

NYSEARCA:KAPA (5/7/2025, 10:32:06 AM)

0.8125

-0.04 (-5.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/amc
Earnings (Next)N/A N/A
Inst Owners2.97%
Inst Owner Change-91.27%
Ins Owners48.95%
Ins Owner Change0.1%
Market Cap13.56M
Analysts82.22
Price Target8.5 (946.15%)
Short Float %0.28%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.41%
PT rev (3m)-7.41%
EPS NQ rev (1m)-75%
EPS NQ rev (3m)-75%
EPS NY rev (1m)-100%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.07
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.2
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.78%
ROE -82.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 2.84
Altman-Z 2.37
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-44.58%
EPS Next 2Y-43.11%
EPS Next 3Y-45.56%
EPS Next 5Y-42.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-200.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y122.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.95%
OCF growth 3YN/A
OCF growth 5YN/A